HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,514,686 | +0.1% | 1,034,415 | -5.4% | 0.00% | 0.0% |
| Q2 2023 | $39,456,361 | -7.8% | 1,093,883 | -2.4% | 0.00% | -20.0% |
| Q1 2023 | $42,807,744 | -32.9% | 1,120,915 | -0.1% | 0.01% | -28.6% |
| Q4 2022 | $63,835,769 | +86.9% | 1,121,894 | +29.8% | 0.01% | +40.0% |
| Q3 2022 | $34,163,000 | -9.6% | 864,041 | +0.5% | 0.01% | 0.0% |
| Q2 2022 | $37,811,000 | +123.4% | 859,364 | +102.5% | 0.01% | +150.0% |
| Q1 2022 | $16,926,000 | +12.7% | 424,420 | +13.6% | 0.00% | 0.0% |
| Q4 2021 | $15,025,000 | -3.5% | 373,637 | -2.3% | 0.00% | 0.0% |
| Q3 2021 | $15,562,000 | -43.2% | 382,527 | -36.6% | 0.00% | -50.0% |
| Q2 2021 | $27,389,000 | -5.3% | 603,148 | -13.1% | 0.00% | 0.0% |
| Q1 2021 | $28,930,000 | +30.0% | 693,945 | +33.1% | 0.00% | +33.3% |
| Q4 2020 | $22,261,000 | +62.8% | 521,200 | +0.2% | 0.00% | 0.0% |
| Q3 2020 | $13,673,000 | +75.0% | 520,265 | +78.5% | 0.00% | +50.0% |
| Q2 2020 | $7,814,000 | -20.0% | 291,462 | -46.3% | 0.00% | -33.3% |
| Q1 2020 | $9,765,000 | -6.2% | 542,736 | -7.6% | 0.00% | +50.0% |
| Q4 2019 | $10,409,000 | +27.1% | 587,075 | +11.2% | 0.00% | 0.0% |
| Q3 2019 | $8,191,000 | +28.5% | 528,091 | +42.4% | 0.00% | 0.0% |
| Q2 2019 | $6,372,000 | +44.6% | 370,841 | +35.5% | 0.00% | +100.0% |
| Q1 2019 | $4,406,000 | -33.3% | 273,697 | -39.4% | 0.00% | -50.0% |
| Q4 2018 | $6,605,000 | -38.9% | 451,478 | -24.1% | 0.00% | -33.3% |
| Q3 2018 | $10,805,000 | -28.2% | 594,639 | -33.4% | 0.00% | -25.0% |
| Q2 2018 | $15,056,000 | -7.8% | 892,403 | +7.0% | 0.00% | -20.0% |
| Q1 2018 | $16,333,000 | +40.1% | 833,676 | +44.9% | 0.01% | +66.7% |
| Q4 2017 | $11,656,000 | +19.6% | 575,381 | +2.6% | 0.00% | 0.0% |
| Q3 2017 | $9,742,000 | +43.2% | 560,868 | +5.7% | 0.00% | +50.0% |
| Q2 2017 | $6,803,000 | -48.7% | 530,611 | -48.1% | 0.00% | 0.0% |
| Q1 2017 | $13,256,000 | +9.5% | 1,022,920 | -16.5% | 0.00% | 0.0% |
| Q4 2016 | $12,110,000 | +175.7% | 1,225,572 | +237.0% | 0.00% | 0.0% |
| Q3 2016 | $4,393,000 | +43.1% | 363,703 | +2.3% | 0.00% | +100.0% |
| Q2 2016 | $3,069,000 | +9.3% | 355,607 | +19.8% | 0.00% | 0.0% |
| Q1 2016 | $2,809,000 | -34.3% | 296,757 | +20.3% | 0.00% | -50.0% |
| Q4 2015 | $4,276,000 | +0.9% | 246,751 | -21.8% | 0.00% | 0.0% |
| Q3 2015 | $4,239,000 | -52.2% | 315,653 | -19.6% | 0.00% | -33.3% |
| Q2 2015 | $8,866,000 | +112.2% | 392,657 | +34.2% | 0.00% | +50.0% |
| Q1 2015 | $4,178,000 | +39.9% | 292,545 | -5.5% | 0.00% | +100.0% |
| Q4 2014 | $2,986,000 | -8.8% | 309,460 | -14.0% | 0.00% | 0.0% |
| Q3 2014 | $3,274,000 | +10.2% | 359,748 | +19.7% | 0.00% | 0.0% |
| Q2 2014 | $2,971,000 | -34.5% | 300,646 | -15.8% | 0.00% | -50.0% |
| Q1 2014 | $4,538,000 | -21.0% | 357,182 | -6.7% | 0.00% | 0.0% |
| Q4 2013 | $5,741,000 | +41.0% | 383,036 | +3.8% | 0.00% | 0.0% |
| Q3 2013 | $4,073,000 | +44.0% | 368,915 | +3.7% | 0.00% | +100.0% |
| Q2 2013 | $2,829,000 | – | 355,675 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |